Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Pain assessment and factors influencing pain during bone marrow aspiration: A prospective study.

Gendron N, Zia Chahabi S, Poenou G, Rivet N, Belleville-Rolland T, Lemaire P, Escuret A, Ciaudo M, Curis E, Gaussem P, Siguret V, Darnige L.

PLoS One. 2019 Aug 29;14(8):e0221534. doi: 10.1371/journal.pone.0221534. eCollection 2019.

2.

Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.

Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA, Lecompte T, Gouin-Thibault I.

J Thromb Haemost. 2019 Oct;17(10):1670-1682. doi: 10.1111/jth.14541. Epub 2019 Jul 9.

PMID:
31215111
3.

Multifactorial hypercoagulable state associated with a thrombotic phenotype in phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG): Case report and brief review of the literature.

Lefrère B, Stepanian A, Charles P, Foulon-Pinto G, Béranger N, Alhenc-Gelas M, Drouet L, Siguret V.

Thromb Res. 2019 Jun;178:75-78. doi: 10.1016/j.thromres.2019.04.010. Epub 2019 Apr 9. No abstract available.

PMID:
30991241
4.

[Von Willebrand disease in the elderly].

Itzhar-Baïkian N, Veyradier A, Dillinger JG, Stepanian A, Pautas É, Siguret V.

Rev Prat. 2018 Dec;68(10):1125-1131. French.

PMID:
30869223
5.

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Rodrigues Botton M, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Haug KBF, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Loriot MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C.

Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491. doi: 10.1002/cpt.1323. Epub 2019 Feb 17.

PMID:
30506689
6.

Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood: A diagnostic test study.

Pailleret C, Jourdi G, Siguret V, Gouin-Thibault I, Gandrille S, Stepanian A, Curis E, Golmard JL, Gaussem P, Le Bonniec B, Samama CM.

Eur J Anaesthesiol. 2019 Jun;36(6):449-456. doi: 10.1097/EJA.0000000000000903.

PMID:
30308522
7.

FXa-α2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo.

Jourdi G, Gouin-Thibault I, Siguret V, Gandrille S, Gaussem P, Le Bonniec B.

Thromb Haemost. 2018 Sep;118(9):1535-1544. doi: 10.1055/s-0038-1667014. Epub 2018 Aug 2.

PMID:
30071567
8.

Erratum to "Thrombin generation test: A reliable tool to evaluate the pharmacodynamics of vitamin K antagonist rodenticides in rats" [Pestic. Biochem. Physiol. 146 (2018) 19-24].

Jourdi G, Lefèbvre S, Le Bonniec B, Curis E, Gaussem P, Lattard V, Siguret V.

Pestic Biochem Physiol. 2018 Jul;149:149. doi: 10.1016/j.pestbp.2018.05.003. Epub 2018 May 16. No abstract available.

PMID:
30033011
10.

Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome.

Lefrère B, Stepanian A, Itzhar-Baïkian N, Charles P, Hadj-Ali A, Joly B, Alhenc-Gelas M, Drouet L, Veyradier A, Siguret V.

Ann Biol Clin (Paris). 2018 Apr 1;76(2):217-223. doi: 10.1684/abc.2018.1324.

PMID:
29623892
11.

Vitamin K antagonists and emergencies.

Lapostolle F, Siguret V, Martin AC, Pailleret C, Vigué B, Zerbib Y, Tazarourte K.

Eur J Emerg Med. 2018 Dec;25(6):378-386. doi: 10.1097/MEJ.0000000000000541. Review.

PMID:
29462053
12.

Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?

Jabet A, Stepanian A, Golmard JL, Flaujac C, Joly BS, Gouin-Thibault I, Siguret V.

Chest. 2018 Jan;153(1):288-290. doi: 10.1016/j.chest.2017.09.047. No abstract available.

PMID:
29307427
13.

Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.

Melkonian M, Jarzebowski W, Pautas E, Siguret V, Belmin J, Lafuente-Lafuente C.

J Thromb Haemost. 2017 Jul;15(7):1500-1510. doi: 10.1111/jth.13697. Epub 2017 May 11. Review.

14.

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.

Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA.

J Thromb Haemost. 2017 Feb;15(2):273-283. doi: 10.1111/jth.13577. Epub 2017 Feb 6.

15.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
16.

Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban.

Jourdi G, Siguret V, Martin AC, Golmard JL, Godier A, Samama CM, Gaussem P, Gouin-Thibault I, Le Bonniec B.

Thromb Haemost. 2015 Jul;114(1):78-86. doi: 10.1160/TH14-10-0877. Epub 2015 Mar 12.

PMID:
25761505
17.

Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening.

Siguret V, Emmerich J, Belleville T, Golmard JL, Mazoyer E, Gouin-Thibault I, Pautas E.

J Gerontol A Biol Sci Med Sci. 2015 Aug;70(8):977-81. doi: 10.1093/gerona/glu240. Epub 2015 Feb 9.

PMID:
25665832
18.

Multimodal assessment of non-specific hemostatic agents for apixaban reversal.

Martin AC, Gouin-Thibault I, Siguret V, Mordohay A, Samama CM, Gaussem P, Le Bonniec B, Godier A.

J Thromb Haemost. 2015 Mar;13(3):426-36. doi: 10.1111/jth.12830. Epub 2015 Feb 5.

19.

[Determination of full blood count normal reference values for adults in France].

Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C, Luce JC, Maldonado E, Siguret V, Tichet J, Lantieri O, Corberand J; Groupe francophone d'hématologie cellulaire (GFHC).

Ann Biol Clin (Paris). 2014 Sep-Oct;72(5):561-81. doi: 10.1684/abc.2014.0979. French.

20.

[Evaluation of the impact of a training program on vitamin K antagonists (VKA) implemented by pharmacy students aiming at improving the knowledge of patients receiving vitamin K antagonists during their hospital clinical training course].

Conort O, Siguret V, Bourdon O, Nazaraly S, Brignone M, Pons-Kerjean N, Houze S, Laribe Cage S, Berthet F, Golmard JL, Brion F, Tilleul P.

Ann Pharm Fr. 2014 Jul;72(4):287-95. doi: 10.1016/j.pharma.2014.02.004. Epub 2014 Mar 27. French.

PMID:
24997889
21.

Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia.

Noris P, Schlegel N, Klersy C, Heller PG, Civaschi E, Pujol-Moix N, Fabris F, Favier R, Gresele P, Latger-Cannard V, Cuker A, Nurden P, Greinacher A, Cattaneo M, De Candia E, Pecci A, Hurtaud-Roux MF, Glembotsky AC, Muñiz-Diaz E, Randi ML, Trillot N, Bury L, Lecompte T, Marconi C, Savoia A, Balduini CL, Bayart S, Bauters A, Benabdallah-Guedira S, Boehlen F, Borg JY, Bottega R, Bussel J, De Rocco D, de Maistre E, Faleschini M, Falcinelli E, Ferrari S, Ferster A, Fierro T, Fleury D, Fontana P, James C, Lanza F, Le Cam Duchez V, Loffredo G, Magini P, Martin-Coignard D, Menard F, Mercier S, Mezzasoma A, Minuz P, Nichele I, Notarangelo LD, Pippucci T, Podda GM, Pouymayou C, Rigouzzo A, Royer B, Sie P, Siguret V, Trichet C, Tucci A, Saposnik B, Veneri D; European Hematology Association – Scientific Working Group on Thrombocytopenias and Platelet Function Disorders.

Haematologica. 2014 Aug;99(8):1387-94. doi: 10.3324/haematol.2014.105924. Epub 2014 Apr 24.

22.

[Management of vitamin K antagonists in the elderly].

Belleville T, Pautas É, Gaussem P, Siguret V.

Ann Biol Clin (Paris). 2014 Mar-Apr;72(2):185-92. doi: 10.1684/abc.2014.0933. Review. French.

23.

[Relationship between maintenance dosages of fluindione (Préviscan) and warfarin (Coumadin) for patients 70 years and older].

Pautas É, Peyron I, Gouin-Thibault I, Gouronnec A, Monti A, Bouhadiba S, Badie C, Golmard JL, Siguret V.

Rev Med Interne. 2015 Jan;36(1):7-9. doi: 10.1016/j.revmed.2013.11.017. Epub 2013 Dec 27. French.

PMID:
24373728
24.

[Accreditation of automated complete blood count by the LH750 Analyzer (Beckman Coulter) in Georges Pompidou Hospital (Paris, France)].

Robinet S, Lemaire P, Louis G, Vieillefond V, Daigneau Y, Gaillaud E, Vincent B, Fischer AM, Siguret V.

Ann Biol Clin (Paris). 2013 Nov-Dec;71(6):717-30. doi: 10.1684/abc.2013.0892. French.

25.

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.

Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V.

Thromb Haemost. 2014 Apr 1;111(4):705-12. doi: 10.1160/TH13-07-0555. Epub 2013 Dec 12.

PMID:
24337438
26.

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.

Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T.

Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.

PMID:
24172843
27.

Full blood count normal reference values for adults in France.

Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C, Luce JC, Maldonado E, Siguret V, Tichet J, Lantieri O, Corberand J; French-Speaking Cellular Hematology Group (Groupe Francophone d'Hématologie Cellulaire, GFHC).

J Clin Pathol. 2014 Apr;67(4):341-4. doi: 10.1136/jclinpath-2013-201687. Epub 2013 Oct 29.

PMID:
24170208
28.

Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Siguret V, Gouin-Thibault I, Gaussem P, Pautas E.

Drugs Aging. 2013 Sep;30(9):687-99. doi: 10.1007/s40266-013-0101-0. Review.

PMID:
23884865
29.

[Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists].

Cambus JP, Magnin D, Ambid-Lacombe C, Bura A, Desgrippes F, Schneller JM, Benhamou Y, Flaujac C, Horellou MH, De Raucourt E, Kaczan D, Astoul JM, Siguret V.

Rev Med Interne. 2013 Sep;34(9):515-21. doi: 10.1016/j.revmed.2013.02.001. Epub 2013 Mar 22. French.

PMID:
23523077
30.

Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement.

Moreau C, Bajolle F, Siguret V, Loriot MA, Bonnet D.

J Thromb Haemost. 2013 Mar;11(3):555-72. doi: 10.1111/jth.12105. No abstract available.

31.

Anemia in the elderly: usefulness of an easy and comprehensive laboratory screen.

Pautas E, Siguret V, Kim TM, Chaïbi P, Golmard JL, Gouronnec A, Nivet-Antoine V, Gouin-Thibault I.

Ann Biol Clin (Paris). 2012 Nov-Dec;70(6):643-7. doi: 10.1684/abc.2012.0746.

32.

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C.

Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7. Review.

33.

[Vitamin K antagonists: from discovery to pharmacogenetics].

Moreau C, Loriot MA, Siguret V.

Ann Biol Clin (Paris). 2012 Oct 1;70(5):539-51. doi: 10.1684/abc.2012.0740. Review. French.

34.

Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.

Smires FZ, Moreau C, Habbal R, Siguret V, Fadili S, Golmard JL, Assaidi A, Beaune P, Loriot MA, Nadifi S.

J Clin Pharm Ther. 2012 Oct;37(5):594-8. doi: 10.1111/j.1365-2710.2012.01340.x. Epub 2012 Apr 8.

PMID:
22486182
35.

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, Loriot MA.

Blood. 2012 Jan 19;119(3):861-7. doi: 10.1182/blood-2011-07-365502. Epub 2011 Nov 30.

36.

No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy.

Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A.

J Thromb Haemost. 2011 Oct;9(10):1966-72. doi: 10.1111/j.1538-7836.2011.04458.x.

37.

[Management of complications with antivitamin K in elderly people].

Pautas E, Mitha N, Gouronnec A, Siguret V, Gouin-Thibault I.

Soins Gerontol. 2011 May-Jun;(89):12-6. French.

PMID:
21698957
38.

[Divisibility of warfarin and fluindione tablets tested in elderly patients and their family circle].

Pautas E, Despres J, Peyron I, Golmard JL, Grange J, Koenig N, Gouronnec A, Mitha N, Siguret V, Gouin-Thibault I.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Jun;9(2):171-7. doi: 10.1684/pnv.2011.0269. French.

PMID:
21690025
39.

[Hodgkin lymphoma in the elderly].

Belleville T, Bouhadiba S, Fontaine J, Gouin-Thibault I, Gouronnec A, Le Tourneau A, Monti A, Pautas E, Siguret V.

Ann Biol Clin (Paris). 2011 May-Jun;69(3):319-24. doi: 10.1684/abc.2011.0529. French.

40.

Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INR response after vitamin K administration.

Pautas E, Peyron I, Bouhadiba S, Golmard JL, Gouronnec A, Oboa N, Siguret V, Gouin-Thibault I.

Am J Med. 2011 Jun;124(6):527-33. doi: 10.1016/j.amjmed.2011.01.016.

PMID:
21605730
41.

Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).

Leizorovicz A, Siguret V, Mottier D; Innohep® in Renal Insufficiency Study Steering Committee, Leizorovicz A, Siguret V, Mottier D, Clonier F, Janas M, Stinson J, Townshend G, Maddalena M.

Thromb Res. 2011 Jul;128(1):27-34. doi: 10.1016/j.thromres.2011.03.002. Epub 2011 Apr 7.

PMID:
21477846
42.

Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.

Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, Loriot MA, Siguret V.

J Thromb Haemost. 2011 Apr;9(4):711-8. doi: 10.1111/j.1538-7836.2011.04213.x.

43.

[Screening for thrombophilic abnormalities in very elderly patients].

Anard-Michelot H, Siguret V, Gouin-Thibault I, Siriwardana M, Gouronnec A, Pautas E.

Ann Biol Clin (Paris). 2010 Nov-Dec;68(6):643-8. doi: 10.1684/abc.2010.0484. French.

44.

Human NK cells display major phenotypic and functional changes over the life span.

Le Garff-Tavernier M, Béziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V.

Aging Cell. 2010 Aug;9(4):527-35. doi: 10.1111/j.1474-9726.2010.00584.x. Epub 2010 May 10.

45.

A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.

Gouin-Thibault I, Siguret V, Pautas E.

Clin Interv Aging. 2010 Apr 26;5:119-21.

46.

Improving anticoagulation control in hospitalized elderly patients on warfarin.

Gouin-Thibault I, Levy C, Pautas E, Cambus JP, Drouet L, Mahé I, Bal Dit Sollier C, Horellou MH, Golmard JL, Siguret V.

J Am Geriatr Soc. 2010 Feb;58(2):242-7. doi: 10.1111/j.1532-5415.2009.02675.x. Epub 2010 Jan 26.

PMID:
20374400
47.

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].

Moreau C, Siguret V, Loriot MA.

Rev Med Interne. 2010 May;31(5):361-8. doi: 10.1016/j.revmed.2009.07.014. Epub 2010 Apr 1. French.

PMID:
20362363
48.

[Elderly patients with myelodysplastic syndrome with del 5q receiving lenalidomide: two case reports with poor prognosis].

Reibel F, Debord C, Bouhadiba S, Chaïbi P, Bilhou-Nabera C, Le Garff M, Gouin-Thibault I, Siguret V.

Ann Biol Clin (Paris). 2010 Mar-Apr;68(2):248-53. doi: 10.1684/abc.2010.0426. French.

49.

[Venous thromboembolism; specific geriatric considerations in care].

Pautas E, Siriwardana M, Gouin-Thibault I, Siguret V.

Soins Gerontol. 2009 Sep-Oct;(79):35-9. French. No abstract available.

PMID:
19813657
50.

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.

Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, Taillandier-Hériche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V.

Clin Pharmacol Ther. 2010 Jan;87(1):57-64. doi: 10.1038/clpt.2009.178. Epub 2009 Sep 30.

PMID:
19794411

Supplemental Content

Loading ...
Support Center